Helicase News and Research

RSS

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.

9 Apr 2021

Research finds polymerase of SARS-CoV-2 can adopt an alternative structure

New research by German scientists has uncovered another form of coronavirus polymerase. The current polymerase thought to be used for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a viral RNA-dependent RNA polymerase (RdRp) for replication and transcription. It contains a monomeric enzyme with the catalytic subunit nsp12, two copies of subunit nsp8, and one copy of subunit nsp7.

28 Mar 2021

Identifying druggable targets on an essential SARS-CoV-2 protein

In a research paper recently uploaded to the preprint server bioRxiv by Newman et al. (March 15th, 2021) the structure and role of one such protein: NSP13, is investigated, with two appealingly druggable targets being identified, possibly opening a new route towards a novel SARS-CoV-2 antiviral agent.

18 Mar 2021

Backtracking occurs within SARS-CoV-2 replication-transcription complex

Researchers continue to achieve a better understanding of SARS-CoV-2, the virus behind the ongoing COVID-19 pandemic. One such effort has been reported in a new preprint on the bioRxiv server, dealing with the phenomenon of backtracking.

16 Mar 2021

Insights into molecular tools shared across coronaviruses could provide potential target for COVID-19

Coronaviruses exploit our cells so they can make copies of themselves inside us. After they enter our cells, they use our cell machinery to make unique tools of their own that help them generate these copies.

22 Feb 2021

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

Researchers provide an overview of SARS-CoV-2 and its life cycle pathways, addressing the functional changes in the viral proteins, providing important strategic clues to help that may help in the ongoing development of therapies against COVID-19.

22 Jan 2021

Research suggests seaweed used in traditional Chinese medicine could protect against COVID-19

Researchers in China have conducted a study showing that a carbohydrate found in the seaweed Ecklonia kurome blocks the activity of an enzyme that is essential for the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Jan 2021

New probes allow scientists to see quadruple-helix DNA in living human cells

New probes allow scientists to see four-stranded DNA interacting with molecules inside living human cells, unravelling its role in cellular processes.

14 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Prior T cell immunity to SARS-CoV-2 unlikely to be the result of seasonal coronavirus infection

Scientists have suggested that a proportion of the population have pre-existing immunity to COVID-19 because of T cells primed against SARS-CoV-2 antigens.

14 Dec 2020

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

By exploiting type 1 interferon's ability to foster an antagonistic cellular environment for viral replication, a research group from France pinpointed DEAD-box RNA helicase DDX42 as an intrinsic inhibitor of HIV, but also other pathogenic viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Chikungunya virus.

29 Oct 2020

Study: SARS-CoV-2 virus adopts new strategy to ensure its replication, spread

Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.

27 Oct 2020

New inhibitor of SARS-CoV-2 RNA translation

As the search for effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitors continues, a recent study by Yale University School of Medicine researchers published on the preprint server bioRxiv in October 2020 reports the inhibitory effect of the drug merofloxacin on frameshifting during SARS-CoV-2 replication.

26 Oct 2020

SARS-CoV-2 mutations dictate severity of COVID-19 disease

A recent study by researchers from Semmelweis University and Pazmany Peter Catholic University in Budapest, Hungary, published on the preprint server medRxiv in October 2020, shows the relationship of specific mutations on the disease's outcome.

22 Oct 2020

Study characterizes biochemical mechanism of cancer-linked enzyme

A new study led by scientists at IUPUI and Indiana University Bloomington is the first to describe a biochemical mechanism that increases the activity of a molecule whose presence is observed in many types of cancer.

21 Oct 2020

Scientists discover a novel antiviral strategy for treating COVID-19

A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.

16 Oct 2020

Pfizer's anti-viral 3CL protease inhibitor shows antiviral potential against SARS-CoV-2

Now, a new study by researchers from Pfizer, University of Arizona, Purdue University, The Scripps Research Institute, and UC San Diego School of Medicine and published on the preprint server bioRxiv in September 2020 reports that an enzyme inhibitor may act in synergism with the approved antiviral remdesivir to suppress viral replication in COVID-19.

16 Sep 2020

Study tracks the mutation rate of SARS-Cov-2 virus

25 Aug 2020

Potential inhibitors of SARS-CoV-2 identified

Now, a new study published on the preprint server bioRxiv in August 2020 reports the discovery of two inhibitors of the helicase enzyme, which is essential for viral replication and the most highly conserved non-structural coronavirus (CoV) protein.

16 Aug 2020

Analysis of the SARS-CoV-2 proteome via visual tools

Now, a new study published on the preprint server bioRxiv* in July 2020 shows how this can be advanced at a greater speed by combining experimental results with homology models obtained by high-throughput pipelines. This will help produce new hypotheses that will show novel druggable targets for effective drug development.

21 Jul 2020